Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer Background <p>Although immunotherapy has revolutionized cancer treatment, its efficacy in castration-resistant prostate cancer (CRPC) remains limited, largely due to an immunologically "cold" tumor microenvironment with scarce T-cell infiltration. Unraveling the molecular mechanisms underlying immune evasion and developing novel strategies to activate innate antitumor immunity are therefore critical to overcoming immunotherapy resistance in CRPC.</p> Methods <p>Using bioinformatic approaches, we analyzed the… Journal for ImmunoTherapy of Cancer January 30, 2026 Original source
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma Background <p>Patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) often respond to cytotoxic therapy, but early disease progression is typical. Responses to immunotherapy alone are rare. Recent advances in chemoimmunotherapy combinations offer promise. We report results from cohorts A and B of REVOLUTION, an adaptive platform trial designed to evaluate the safety and antitumor activity of chemoimmunotherapy combinations in untreated mPDAC.</p>… Journal for ImmunoTherapy of Cancer January 30, 2026 Original source
Advancing ICOS agonism in solid tumors: lessons from INDUCE-1 <p>The inducible T-cell co-stimulator (ICOS, CD278) represents an appealing yet complex target within the CD28 immunoglobulin receptor superfamily. Unlike constitutively expressed co-stimulatory molecules, ICOS is minimally present on naïve T cells and is upregulated following T-cell receptor engagement. This inducible expression pattern, and its crosstalk with other co-stimulatory pathways such as OX40, 4-1BB, CD40, and CD28, position ICOS as a… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells Background <p>Myeloid-derived suppressor cells (MDSCs) have a dominating presence in the postoperative period, mediating the suppression of natural killer (NK) cells and promoting cancer metastases after surgery. However, their phenotype and effects on postoperative cellular immunity remain incompletely understood. This study aims to functionally characterize surgery-induced (sx) MDSCs and identify potential therapeutic strategies to mitigate their immunosuppressive effects.</p> Methods <p>We… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication Background <p>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related deaths. Immune checkpoint inhibitors (ICIs) of programmed death-1 (PD-1)/programmed death ligand-1 signaling induce tumor regression in some patients with NSCLC, but most patients with NSCLC exhibit resistance to ICIs therapy. NSCLC shapes the potent tumor immunosuppressive microenvironment (TIME) that underlies… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy Purpose <p>This study was conducted to assess the clinical significance of programmed cell death-ligand 1 (PD-L1)-positive circulating tumor cells (CTCs) as predictive biomarkers for the efficacy of PD-(L)1 inhibitor-based treatment in advanced hepatocellular carcinoma (HCC).</p> Experimental design <p>We enrolled 59 patients with unresectable HCC who received immunotherapy-based treatment and analyzed CTCs, PD-L1<sup>+</sup>CTCs and molecules in peripheral blood. An innovative telomerase… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model Background <p>Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in hematologic malignancies but faces substantial challenges in solid tumors. One of the main obstacles is the extracellular matrix (ECM), which serves as the physical barrier that hinders T cell infiltration into tumor tissues.</p> Methods <p>We engineered CAR-T cells targeting mesothelin or B7H3 to co-express matrix metalloproteinase-3 (MMP3).… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity Background <p>Insufficient infiltration of CD8<sup>+</sup> T cells in the tumor microenvironment (TME) critically restricts antitumor immunity and cancer immunotherapy efficacy. The purpose of this study was to identify novel tumor cell-intrinsic regulators of T-cell infiltration and to elucidate their mechanisms of action.</p> Methods <p>We performed a genome-wide Sleeping Beauty transposon mutagenesis screen in murine breast cancer models. Protein–protein interactions were… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer Background <p>Nanosecond pulsed electric field (nsPEF) ablation has demonstrated limited and transient efficacy in suppressing tumor progression. Oncolytic peptide LTX-315 is known to elicit a strong antitumor immune response and durable immune memory. This study aimed to investigate whether LTX-315 could enhance nsPEF-induced antitumor immunity in liver cancer.</p> Methods <p>Both cell assays and mouse models were used to evaluate the… Journal for ImmunoTherapy of Cancer January 29, 2026 Original source
<span>l</span>-Fucose: a dietary sugar with multifaceted potential in the biology and therapy of cancer <p>Nature Reviews Cancer, Published online: 27 January 2026; <a href="https://www.nature.com/articles/s41568-025-00901-z">doi:10.1038/s41568-025-00901-z</a></p>The conjugation of glycoproteins and glycolipids with the dietary sugar L-fucose is known as fucosylation. In this Progress article, Bitaraf et al. describe the latest work showing how fucosylation is deregulated in cancer, influencing tumour progression and therapeutic responses, and how it might be leveraged to treat cancer. Nature Reviews Cancer January 28, 2026 Original source
Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial <p>Prostate Cancer and Prostatic Diseases, Published online: 28 January 2026; <a href="https://www.nature.com/articles/s41391-026-01072-0">doi:10.1038/s41391-026-01072-0</a></p>Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial Prostate Cancer Journal January 28, 2026 Original source
Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity Background <p>Tumor-associated macrophages (TAMs) are key drivers of the immunosuppressive tumor microenvironment (TME), thereby limiting the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear.</p> Methods <p>Both genetic (Akr1b3 knockout) and pharmacologic (epalrestat) approaches were employed to examine the impact of Aldo-keto reductase family 1 member B1 (AKR1B1) inhibition on TAMs and T-cell function in vitro and… Journal for ImmunoTherapy of Cancer January 27, 2026 Original source
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma Background <p>Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predicting toxicity remain lacking.</p> Methods <p>In this retrospective, multicenter study, we analyzed pretreatment serum samples from 331 patients with metastatic melanoma treated with anti-CTLA-4 (ipilimumab), anti-PD-1 (pembrolizumab or nivolumab), or combination ipilimumab/nivolumab. IgG autoantibody reactivity against 832 human… Journal for ImmunoTherapy of Cancer January 27, 2026 Original source
Reciprocal regulation of hMENA and TGF-{beta} signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC Background <p>Cancer-associated fibroblasts (CAFs) significantly impact cancer progression and CAF subtypes are key determinants of response to immune checkpoint therapy (ICT). The transforming growth factor-β (TGF-β) signaling is a main pathway in protumorigenic activity of CAFs and resistance to ICT. The actin cytoskeleton regulator hMENA plays crucial roles in epithelial–mesenchymal transition (EMT) and regulates pathways critical to antitumor immune response,… Journal for ImmunoTherapy of Cancer January 27, 2026 Original source
Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery Introduction <p>An adaptive immune response to cancer requires three main signals: antigen presentation and recognition ("signal 1"), costimulation ("signal 2"), and secreted immunostimulatory cytokines ("signal 3"). Expression of these signals in tumors via non-viral gene delivery represents a promising strategy to reprogram the tumor microenvironment (TME) and prime antitumor immunity.</p> Methods <p>We used modular polymeric poly(beta-amino ester)-based nanoparticles (NPs) to… Journal for ImmunoTherapy of Cancer January 27, 2026 Original source
Tumor neoantigen gene C7orf50 remodels the immune microenvironment by recruiting tumor-associated macrophages to promote hepatocellular carcinoma progression and lung metastasis Background <p>Hepatocellular carcinoma (HCC) is a global health challenge with high mortality rates, particularly in patients with advanced disease and lung metastasis. T-cell receptor (TCR)-T cell therapy based on specific neoantigens, is an emerging treatment with potential for HCC. However, the prognosis of patients remains poor, underscoring the need for novel targets and strategies.</p> Methods <p>We conducted a comprehensive study… Journal for ImmunoTherapy of Cancer January 27, 2026 Original source
The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study <p>Prostate Cancer and Prostatic Diseases, Published online: 26 January 2026; <a href="https://www.nature.com/articles/s41391-026-01075-x">doi:10.1038/s41391-026-01075-x</a></p>The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study Prostate Cancer Journal January 26, 2026 Original source
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis <p>Prostate Cancer and Prostatic Diseases, Published online: 26 January 2026; <a href="https://www.nature.com/articles/s41391-026-01077-9">doi:10.1038/s41391-026-01077-9</a></p>Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis Prostate Cancer Journal January 26, 2026 Original source
Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgery Background <p>Oncolytic viruses are tumor-specific immunotherapeutic agents that exploit inherent features of the tumor microenvironment to replicate, spread, and kill cancer cells. The exchange protein activated by cAMP (EPAC) is a cell signaling protein that regulates pathways important for cell growth, survival, and migration, which are commonly associated with cancer progression, but are also very important for regulation of viral… Journal for ImmunoTherapy of Cancer January 24, 2026 Original source